Comparing BL-M07D1 vs DS-8201 for HR-positive, HER2-low breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial compares a new drug, BL-M07D1, to an existing treatment (DS-8201) for women with HR-positive, HER2-low breast cancer that has come back or spread. The goal is to see if the new drug works better or has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- Your breast cancer is HR-positive and HER2-low (low levels of HER2 protein), and has returned or spread to other parts of the body.
- You have not received any anti-HER2 therapy or certain other targeted drugs before.
- You are in reasonably good health (able to do daily activities, no major organ problems, and no active infections).
- You have at least one tumor that can be measured with scans or tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug called BL-B01D1 against standard chemotherapy in patients with advanced breast cancer that is hormone-receptor-positive (HR+) and HER2-negative, and has stopped responding to hormone treatments. The goal is to see if the new drug works better or has fewer side effects.
This Phase 1 study tests BL-M07D1, a new investigational medicine, in people with HER2-positive or HER2-low breast cancer (and other solid tumors) that can’t be operated on or has spread. It aims to find a safe dose and learn how well the treatment may work based on HER2 levels in tumor tissue.
This trial tests two experimental drugs, SI-B003 and BL-B01D1 plus SI-B003, for people with HER2-negative breast cancer that has spread or cannot be removed by surgery. It is for those who have tried standard treatments or cannot have them.
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
This trial tests a new drug, BL-M17D1, for people with advanced breast cancer (HER2 positive or negative) or other solid tumors that have spread. It aims to see if the drug is safe and effective.
This Phase 1 trial tests BL-B01D1 in people with advanced (unresectable or metastatic) breast cancer and certain other solid tumors that have not worked with standard treatment. The goal is to learn if the drug can be given safely and to see whether it shows signs of benefit.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.